ANNX (Annexon) Total Equity: $186.06 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANNX Annexon Inc ANNX
34 GF Score
Price $4.21
! 2 Warning Signs
View Full Analysis

What is Annexon Total Equity?

Annexon ANNX -0.36% 34 Total Equity is $186.06 Mil as of Jun. 2026. GuruFocus rates ANNX with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Annexon's total equity for the quarter that ended in Jun. 2026 was $186.06 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Annexon Total Equity Historical Data

* Premium members only.

The historical data trend for Annexon's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annexon Total Equity Chart

Annexon Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only 231.91 231.19 250.56 293.11 211.65

Annexon Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 199.02 161.44 211.65 204.53 186.06
ANNX
34GF Score
Annexon Inc ANNX
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annexon Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Annexon's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=277.571-65.923
=211.65

Annexon's Total Equity for the quarter that ended in Jun. 2026 is calculated as

Total Equity=Total Assets(Q: Jun. 2026 )-Total Liabilities(Q: Jun. 2026 )
=246.068-60.007
=186.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $186.06 Mil mean?
Annexon (ANNX) has a Total Equity of $186.06 Mil as of Jun. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Annexon and its competitors.
Is Annexon's Total Equity too high?
Annexon's current Total Equity is $186.06 Mil. Overall, Annexon has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Annexon's Total Equity compare to DSGN and GERN?
Annexon's Total Equity of $186.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Annexon and its competitors. Annexon's current Total Equity is $186.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexon stock overvalued right now?
Annexon (ANNX) has a current Total Equity of $186.06 Mil. The current Total Equity is $186.06 Mil. Annexon's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Annexon (ANNX), the current Total Equity is $186.06 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annexon Business Description

Address 1400 Sierra Point Parkway, Suite 200, Building C, Brisbane, CA, USA, 94005
Annexon Inc. is a clinical-stage biopharmaceutical company based in the United States that develops therapies targeting the classical complement pathway, a part of the immune system implicated in autoimmune and neurodegenerative diseases. Its pipeline is built on a platform designed to block C1q and the entire classical complement cascade. The company's lead candidates include ANX005, an intravenous antibody for autoimmune and neurodegenerative disorders such as Guillain-Barré syndrome and Huntington's disease; ANX007, an antibody fragment for neurodegenerative ophthalmic conditions including geographic atrophy; ANX009, for systemic autoimmune diseases; and ANX1502, an oral small-molecule candidate. As a clinical-stage company, Annexon does not yet generate product revenue and funds its operations primarily through equity financings, collaboration arrangements, and licensing. Its activities are centered on research, clinical development, and regulatory interactions in the United States and other markets.
34GF Score

Get the complete analysis for ANNX

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.21
Price